Coronavirus (COVID-19)
Learn more
April 26, 2017
Sponsor: Gynecologic Oncology Group
Number: 286B
Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II/III trial studies how well Paclitaxel, Carboplatin, and Metformin Hydrochloride works and compares it to Paclitaxel, Carboplatin, and placebo in treating patients with endometrial cancer that is stage III, IV, or has come back. (Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety. Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely) . Chemotherapy drugs such as Paclitaxel and Carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Metformin Hydrochloride may help Paclitaxel and Carboplatin work better by making cancer cells more sensitive to the drugs. It is not yet known whether Paclitaxel and Carboplatin are more effective with or without Metformin Hydrochloride in treating endometrial cancer.
Who’s eligible:
Available at: The Hospital of Central Connecticut, Hartford Hospital.
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
To receive our health news text alerts / text StartHere to 85209